2026 Interim report
Filed with HKEX · Stock code 2509 · · 142 pages · English and Chinese
Qyuns Therapeutics Co., Ltd. on 6ix
Earlier from Qyuns Therapeutics
Later from Qyuns Therapeutics
- Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; and resignation and proposed appointment of non-executive director
- List of directors and their roles and functions
- Voluntary announcement phase III clinical study results of Oturkibart (QX005N) for treatment of prurigo nodularis presented as a late-breaking oral presentation at EADV 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Qyuns Therapeutics into a list and get an email when it puts out news.
Follow Qyuns Therapeutics